Can kinase inhibitors achieve therapeutic effects through off-target complement modulation?

OPEN

If validated, Alectinib's C1q interaction represents a novel mechanism where kinase inhibitors modulate innate immunity. This could reveal new therapeutic opportunities for repurposing kinase drugs in neuroinflammatory diseases. Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e (Analysis: SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e)

Priority: 0.70 Domain: pharmacology Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: Can kinase inhibitors achieve therapeutic effects through off-target complement modulation? is a 0.7 priority gap in pharmacology. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Can kinase inhibitors achieve therapeutic effects through off-target complement modulation? — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.00

Avg Quality

Resolution

Mechanistic Families

Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps